



REDEFINING IMMUNO-ONCOLOGY

## Genelux Corporation to Participate in Upcoming Conferences

February 18, 2026

WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- [Genelux Corporation](#) (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences.

- **Oppenheimer Healthcare Life Sciences Conference:** Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.
- **TD Cowen 46th Annual Health Care Conference:** Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, Chief Financial Officer, will participate in a presentation on Monday, March 2, 2026, at 2:30 p.m. ET in Boston, MA.

Live webcasts of the fireside chat and presentation can be found on the Events & Presentations section of the Company's Investor Relations website at <https://investors.genelux.com/news-events/events-presentations>. Following the completion of the events, an archived replay of each webcast will be available on the Company's Investor Relations website.

### About Genelux Corporation

Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b/2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which Genelux has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.

### Investor Contact

Austin Murtagh  
Precision AQ  
[austin.murtagh@precisionaq.com](mailto:austin.murtagh@precisionaq.com)

### Media Contact

Ashley Murphy  
Precision AQ  
[ashley.murphy@precisionaq.com](mailto:ashley.murphy@precisionaq.com)

Source: Genelux Corporation



Source: Genelux Corporation